Artesunate is an antimalarial drug that has shown promise in treating various types of cancer, including pancreatic cancer. However, the recommended dosage of artesunate for pancreatic cancer is not clearly established.

According to the Drug Patent Watch [1], the recommended dosage of artesunate for malaria treatment is 2.4 mg/kg/day for three days. However, this dosage may not be applicable for pancreatic cancer treatment.

A study published in the Journal of Cancer Research and Therapeutics [2] reported that artesunate was effective in inhibiting the growth of pancreatic cancer cells in vitro and in vivo. The study used a dosage of 50 mg/kg/day of artesunate in mice, which was found to be effective in reducing tumor growth.

Another study published in the Journal of Translational Medicine [3] investigated the efficacy of artesunate in combination with gemcitabine, a chemotherapy drug commonly used to treat pancreatic cancer. The study used a dosage of 200 mg/day of artesunate in combination with gemcitabine, which was found to be safe and effective in treating pancreatic cancer patients.

In summary, the recommended dosage of artesunate for pancreatic cancer is not clearly established. However, based on the available studies, a dosage of 50 mg/kg/day in mice and 200 mg/day in combination with gemcitabine in humans have shown promise in treating pancreatic cancer. Further research is needed to establish the optimal dosage of artesunate for pancreatic cancer treatment.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/ARTESUNATE
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564301/
[3] https://pubmed.ncbi.nlm.nih.gov/19690861/